



INVESTMENTS
IN AMR R&D

ANTIBACTERIALS IN
CLINICAL DEVELOPMENT

INCENTIVES FOR
ANTIBACTERIAL R&D

OVERVIEW OF THE THREE GALLERIES

Investments on human and animal-health related AMR R&D

Investments since January 2017 from public and not-for profit private funders into AMR R&D related to human bacterial infections and animal pathogens

As at September 2020, a total captured of ...

7496
projects

141
funders

5.6bn
USD

Geographical coverage of investments

34
countries + EU

5
continents

28%
investment at
international
level

Most funding is directed towards ...

30%
basic research

41%
product-related
R&D

22%
support for
operational and
implementation
research



Pipeline of human antibacterials in clinical development

Remains fragile, with low numbers and relatively weak innovativeness and with only about two fifths of the compounds in development or recently approved addressing some of the most critical pathogens

Incentives for antibacterial R&D

Late-stage push incentives for the later, more expensive stages of therapeutic development, concentrated in a few funders.

Pull incentives remain *ad hoc*, small-scale and initiated by just a few countries globally.

Conclusion and next steps

First consolidation of national AMR-related R&D funding

Report provides a baseline, representing two full years of data (2017 and 2018).

The outcomes and resulting analysis will help to identify opportunities and gaps in AMR R&D and inform about progress in the AMR R&D field